AWM
AKRO

Avior Wealth Management’s Akero Therapeutics AKRO Stock Holding History

Avior Wealth Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12
Closed -$303 – 2295
2024
Q1 		$303 Buy
+12
New +$288 ﹤0.01% 2722

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Avior Wealth Management's AKRO Position: Q2 2024 in Review

Avior Wealth Management sold out of Akero Therapeutics (AKRO) in Q2 2024, closing a stake of 12 shares — an estimated $303 sold.

Avior Wealth Management first reported a position in AKRO in Q1 2024 and held it in 1 quarter. The position peaked at $303 in Q1 2024. 153 funds tracked by Wall St. Rank hold AKRO as of Q2 2024.

  • Avior Wealth Management reported no remaining Akero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 12 Akero Therapeutics shares in Q2 2024, an estimated $303.
  • Avior Wealth Management first reported a position in Akero Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Akero Therapeutics position peaked at $303 in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.